Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Ovid Therapeutics (OVID) Shares Outstanding (Diluted Average) (2020 - 2026)

Ovid Therapeutics filings provide 7 years of Shares Outstanding (Diluted Average) readings, the most recent being $136.2 million for Q1 2026.

  • Quarterly Shares Outstanding (Diluted Average) rose 10893611.44% to $136.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $136.2 million through Mar 2026, up 10893611.44% year-over-year, with the annual reading at $73.7 million for FY2025, 5898748.48% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $136.2 million in Q1 2026 for Ovid Therapeutics, up from $73.7 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $136.2 million in Q1 2026 and bottomed at $1250.0 in Q4 2023.
  • Average Shares Outstanding (Diluted Average) over 5 years is $58.1 million, with a median of $70.5 million recorded in 2023.
  • The largest annual shift saw Shares Outstanding (Diluted Average) crashed 100.0% in 2025 before it soared 10893611.44% in 2026.
  • Ovid Therapeutics' Shares Outstanding (Diluted Average) stood at $70.4 million in 2022, then crashed by 100.0% to $1250.0 in 2023, then changed by 0.0% to $1250.0 in 2024, then soared by 5898748.48% to $73.7 million in 2025, then skyrocketed by 84.68% to $136.2 million in 2026.
  • Per Business Quant, the three most recent readings for OVID's Shares Outstanding (Diluted Average) are $136.2 million (Q1 2026), $73.7 million (Q4 2025), and $71.1 million (Q3 2025).